The first evidence of a cytolytic human immune response against CML BCR-ABL oncogene-derived peptides was described by Bocchia et al. who demonstrated that peptides derived from amino acid sequences crossing the b3a2 fusion breakpoint in p210 elicit class I restricted cytotoxic T cells and class II-mediated T cell proliferation, respectively, in vitro[22,23]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.